München
24.10.25 | 08:04
0,988 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Diamyd Medical AB Ser. B Q4 Loss Widens | - | RTTNews | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 08.10. | DIAMYD MEDICAL AB: Year-End Report 24/25 | 1 | Cision News | ||
| 08.10. | Diamyd Medical AB (publ): Year-End Report 24/25 | 171 | GlobeNewswire (Europe) | September 2024 - August 2025, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Type 1 Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen | |
| 03.10. | DIAMYD MEDICAL AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 1 | Cision News | ||
| 03.10. | Diamyd Medical AB (publ): Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 93 | GlobeNewswire (Europe) | Diamyd Medical has been granted a patent in Hong Kong protecting the use of insulin-based antigens to treat individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker. The patent is valid... ► Artikel lesen | |
| 11.09. | DIAMYD MEDICAL AB: New analysis to be presented at EASD supports potential of Diamyd to delay the progression of Stage 3 Type 1 Diabetes | 2 | Cision News | ||
| 10.09. | DIAMYD MEDICAL AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 2 | Cision News | ||
| 10.09. | Diamyd Medical AB (publ): Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 104 | GlobeNewswire (Europe) | The Eurasian Patent Office has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of individuals with type 1 diabetes carrying the HLA... ► Artikel lesen | |
| 05.09. | DIAMYD MEDICAL AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference | 1 | Cision News | ||
| 22.07. | DIAMYD MEDICAL AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June | 1 | Cision News | ||
| 25.06. | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| 25.06. | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 174 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 161 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| 15.05. | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 4 | Cision News | ||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 45,960 | +0,29 % | Novo Nordisk Aktie: Analysten sehen Preisdebatte um Abnehmpräparaten gelassen | Nach den jüngsten Aussagen von US-Präsident Donald Trump zu möglichen Preissenkungen bei Abnehmpräparaten bleiben Analysten bei ihren Einschätzungen zur Novo Nordisk Aktie unverändert. Die Kursziele... ► Artikel lesen | |
| ABBVIE | 196,00 | -0,31 % | AbbVie erzielt positive Studienergebnisse mit RINVOQ bei rheumatoider Arthritis | Der US-Pharmakonzern AbbVie hat in einer späten klinischen Studie positive Ergebnisse für seinen Wirkstoff Upadacitinib (Handelsname RINVOQ) erzielt. In der Phase-3b/4-Studie SELECT-SWITCH wurde das... ► Artikel lesen | |
| ABBOTT LABORATORIES | 108,78 | +0,02 % | A Look Into Abbott Laboratories Inc's Price Over Earnings | ||
| ZOETIS | 126,18 | +0,11 % | What to Expect From Zoetis' Q3 2025 Earnings Report | ||
| AXSOME THERAPEUTICS | 110,50 | +1,01 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of... ► Artikel lesen | |
| DAIICHI SANKYO | 22,790 | -1,09 % | Daiichi Sankyo: Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial | An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the phase 2 part of REJOICE-Ovarian01
Phase 3 part of REJOICE-Ovarian01... ► Artikel lesen | |
| TRULIEVE CANNABIS | 6,415 | -0,77 % | Top U.S. Marijuana Stocks to Watch in October 2025: Trulieve, Curaleaf, and Green Thumb Dominate the Industry | ||
| CATALYST PHARMACEUTICALS | 18,190 | +1,96 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 | ||
| ACADIA PHARMACEUTICALS | 18,510 | -1,07 % | This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | ||
| BRIDGEBIO PHARMA | 46,170 | -0,35 % | BridgeBio Pharma stock rating reiterated as Overweight by Wells Fargo | ||
| TG THERAPEUTICS | 28,720 | -0,35 % | TG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment | During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI... ► Artikel lesen | |
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 10,060 | +0,88 % | Aurinia to present new voclosporin data at rheumatology conferences | ||
| CAMURUS | 56,85 | -4,53 % | INDEX-MONITOR: Fraport, Nordex, Flatexdegiro im Stoxx 600 | FRANKFURT (dpa-AFX) - Zu den sieben im September neuen Unternehmen im Stoxx Europe 600 zählen auch drei deutsche. Zugleich werden aber auch drei deutsche Unternehmen den Index verlassen müssen. Von... ► Artikel lesen | |
| CENTR BRANDS | 0,032 | 0,00 % | Centr Brands Corp (2): Centr Brands extends debenture by one year to 2026 |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,988 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.